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Fluorescent image-guided surgery in breast
cancer by intravenous application of a
quenched fluorescence activity-based
probe for cysteine cathepsins in a
syngeneic mouse model
Frans V. Suurs1†, Si-Qi Qiu1,2*†, Joshua J. Yim3, Carolien P. Schröder1, Hetty Timmer-Bosscha1, Eric S. Bensen4,
John T. Santini Jr4, Elisabeth G. E. de Vries1, Matthew Bogyo3,5,6 and Gooitzen M. van Dam7,8*
Abstract
Purpose: The reoperation rate for breast-conserving surgery is as high as 15–30% due to residual tumor in the
surgical cavity after surgery. In vivo tumor-targeted optical molecular imaging may serve as a red-flag technique to
improve intraoperative surgical margin assessment and to reduce reoperation rates. Cysteine cathepsins are
overexpressed in most solid tumor types, including breast cancer. We developed a cathepsin-targeted, quenched
fluorescent activity-based probe, VGT-309, and evaluated whether it could be used for tumor detection and image-
guided surgery in syngeneic tumor-bearing mice.
Methods: Binding specificity of the developed probe was evaluated in vitro. Next, fluorescent imaging in BALB/c mice
bearing a murine breast tumor was performed at different time points after VGT-309 administration. Biodistribution of
VGT-309 after 24 h in tumor-bearing mice was compared to control mice. Image-guided surgery was performed at
multiple time points tumors with different clinical fluorescent camera systems and followed by ex vivo analysis.
Results: The probe was specifically activated by cathepsins X, B/L, and S. Fluorescent imaging revealed an increased
tumor-to-background contrast over time up to 15.1 24 h post probe injection. In addition, VGT-309 delineated tumor
tissue during image-guided surgery with different optical fluorescent imaging camera systems.
Conclusion: These results indicate that optical fluorescent molecular imaging using the cathepsin-targeted probe,
VGT-309, may improve intraoperative tumor detection, which could translate to more complete tumor resection when
coupled with commercially available surgical tools and techniques.
Keywords: Image-guided surgery (IGS), Quenched fluorescent activity-based probe (qABP), Cathepsin targeting,
Indocyanine green (ICG), Breast cancer
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Introduction
Breast cancer is the most commonly diagnosed cancer and
the leading cause of cancer-related mortality in females
worldwide [1]. Surgical resection is the standard of care pri-
mary treatment modality for patients with early breast can-
cer. Combined with radiotherapy, breast-conserving surgery
demonstrates comparable patient outcome with mastectomy,
while preventing unnecessary excision of normal breast tis-
sue [2, 3]. Local recurrence is mainly due to residual tumor
in the surgical cavity. The risk of local recurrence is reduced
by reoperation if a tumor-positive margin is found by histo-
pathological examination [4]. An important downside of the
use of breast-conserving surgery is the high reoperation rate
after the initial lumpectomy, ranging from 15 to 30% [5, 6].
Current methods for intraoperative margin assessment in
breast-conserving surgery include gross pathologic examin-
ation, frozen section analysis, imprint cytology, and radiofre-
quency spectroscopy (MarginProbe). While these techniques
have been shown to reduce high reoperation rates during
breast-conserving surgery, there is insufficient evidence that
they are effective when baseline rates are below 20% [7].
Drawbacks to these methods include sampling bias and error
due to the small amount of tissue analyzed during frozen
section and imprint cytology analysis, the need for an experi-
enced cytopathologist for accurate imprint cytology inter-
pretation, and high false-positive rates observed with the
MarginProbe device [8]. Therefore, there is an unmet need
for new techniques to improve positive margin detection in-
traoperatively and consequently reduce reoperation rates.
Tumor-targeted optical molecular imaging provides an op-
portunity to identify malignant lesions in the tumor bed and
could potentially meet this need. Particularly, probes acti-
vated by tumor-specific enzymes offer high tumor-to-
background contrast because inactivated agents yield little
signal [9, 10].
Cysteine cathepsin proteases are a class of highly evo-
lutionarily conserved lysosomal enzymes that play an
important role in neoplastic transformation [11]. The se-
creted cathepsins degrade extracellular matrix and cleave
cell-cell adhesion molecules, which promote tumor cell
invasion and metastasis [12, 13]. In human cancers, in-
cluding breast cancer, cathepsin expression is frequently
increased compared with normal tissue [14].
In breast cancer, cathepsins B, L, C, and S are highly
expressed in the tumor tissue and are associated with
poor patient outcomes [11]. Cathepsins can be expressed
on cancer cells as well as immune cells such as macro-
phages [11, 13]. This data provided the rationale for tar-
geting cathepsins with a molecular imaging agent to
improve intraoperative tumor margin assessment. We
evaluated an activity-based approach. This method pro-
vides low-background signal and high-contrast fluores-
cent images after activation of the probe. Upon covalent
and irreversible binding to the active site of an enzyme,
a fluorescently quenched activity-based probe (qABP) is
activated and emits the fluorescent signal [15]. BMV109,
a qABP probe containing a Cy5 fluorophore for tumor
detection covalently binds to active cysteine cathepsins
[16]. It has demonstrated in vivo tumor labeling when
administered by intravenous injection in murine breast
and colon cancer models as well as labeling of the hu-
man breast, lung, liver, pancreas, and colon cancer tis-
sues when applied topically [9, 16, 17].
To ensure compatibility with commercially available,
near-infrared surgical imaging systems and facilitate rapid
clinical translation, a new qABP, VGT-309, was developed
by replacing the Cy5 fluorophore in BMV109 with indocy-
anine green (ICG) and the sulfo-QSY21 quencher with
QC-1 (Fig. 1a and Fig. S1). ICG has longer excitation and
emission wavelengths and is approved by the US Food
and Drug Administration (FDA) and European Medicines
Agency (EMA) for human use. In this proof of concept
study, we evaluated VGT-309 for in vivo tumor detection
and guiding surgical tumor excision using different clinical
imaging devices in a 4T1 mammary tumor allograft
model. In addition, we investigated which cellular sources
in the tumor would contribute to the signal of VGT-309.
Materials and methods
Probe and cell lines
qABP VGT-309 was provided by Vergent Biosciences,
Minnesota. The synthesis and evaluation of the related
qABP BMV109, which selectively targets a broad
spectrum of cathepsins, has been previously reported
[16]. The probe used in this study, VGT-309, uses the
same cathepsin recognition sequence and phenoxy-
methyl ketone as BMV109, but here the far-red Cy5
fluorophore is replaced with the near-infrared ICG
(Intrace Medical) and the sulfo-QSY21 quencher (Life
Technologies Corporation) with QC-1 (LI-COR Biosci-
ences) (Fig. 1a and Supplementary Fig. S1).
The murine breast cancer cell line 4T1 (American
Type Culture Collection) was cultured in RPMI-1640
medium (Invitrogen) containing 10% fetal calf serum
(Bodinco BV). The murine macrophage cell line RAW
264.7 (American Type Culture Collection) was cultured
in Dulbecco’s modified eagle medium (Gibco) containing
10% fetal calf serum.
Cells were used between passages 5–30 after thawing
to ensure complete revival and were routinely tested for
the presence of mycoplasma. Cells were cultured under
aseptic conditions at 37 °C in an incubator providing hu-
midified atmosphere of 5% CO2 in air.
In vitro VGT-309 activation
RAW 264.7 cells were harvested, counted, and diluted to
2 × 106 cells/mL in phosphate-buffered saline (PBS).
The cells were incubated in the presence or absence of
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500 μM of cathepsin inhibitor E64d (Santa Cruz Biotech-
nology) for 30 min at 37 °C followed by the addition of
VGT-309 at the indicated concentrations for 30 min at
37 °C. The cells were spun down at 2287 rcf, the
remaining inhibitor/VGT-309 solution was removed.
The cells were washed twice with PBS by spinning down
and removing the supernatant. The cells were resus-
pended in PBS and put through two freeze-thaw cycles
(snap freeze with liquid nitrogen/40 °C). To each tube,
4x SDS-sample buffer containing 2-mercaptoethanol was
added followed by heating for 3 min at 100 °C. Proteins
were resolved by SDS-PAGE (12%) and the gel was
scanned with an Odyssey CLx Imaging System (LI-COR
Biosciences) on the 800 nm channel to visualize VGT-
309-labeled proteases. Images were analyzed using
Image Studio (LI-COR Biosciences) software.
Animal experiments
Animal experiments were approved by the Institutional
Animal Care and Use Committee of the University of
Groningen and performed according to Dutch law.
Eight- to 10-week-old female BALB/c mice (BALB/
cOlaHsd, Envigo) were allowed to acclimatize for 1 week.
The mice received an alfalfa-free diet. The mice were
injected with 5 × 104 4T1 cells in 50 μL RPMI-1640 in
the lower mammary fat pad. After 19–21 days, the im-
aging experiments were performed when the tumors
reached ± 400 mm3. Mice without tumor implantation
were used as a negative control model. The mice were
intravenously injected with 100 μL of 0.5 mg/mL VGT-
309 (20 nmol). Mice were anesthetized with isoflurane/
medical air inhalation (5% induction, 2.5% maintenance).
In vivo fluorescent imaging
Tumor-bearing mice were imaged with the IVIS Spectrum
(PerkinElmer) at 1, 2, 4, 8, and 24 h after injection. The
control group was imaged 24 h after injection. Six mice
were evaluated at each time point. Settings used for the
IVIS Spectrum were medium binning and FStop 1 with 2 s
exposure. Excitation was at 745 nm with emission at 820
nm. Before imaging, hair was removed via shaving and with
hair removal lotion. After in vivo imaging, mice were sacri-
ficed via cervical dislocation while under anesthesia.
Ex vivo fluorescent imaging
Tissues of interest were collected, namely the tumor, liver,
lung, heart, spleen, kidney, brain, fat, skin, muscle, and
pancreas. They were placed on wet gauzes and imaged
with the Pearl imager (Li-COR Biosciences) before
formalin-fixation in 4% paraformaldehyde (PFA)/PBS and
paraffin embedding. The Pearl imager has an excitation
laser of 785 nm and detects all fluorescence above 820 nm.
For analysis of the images taken with the Pearl, regions of
interests (ROIs) were drawn around the tissues in the
Fig. 1 Mode of action and structure of VGT-309 and in vitro binding to active cysteine cathepsins. a Mode of action of VGT-309. Cathepsins
covalently and irreversibly bind VGT-309, displacing the quencher QC-1. With the quencher displaced, the ICG fluorescence of VGT-309 is no
longer quenched and the probe becomes fluorescent. b Structure of VGT-309. The phenoxymethyl ketone electrophile (red) forms a covalent
bond with the active cysteine of cathepsins. The fluorophore ICG (green) is for visualization and the quencher (gray) prevents fluorescent signal
in the free, unbound probe. c VGT-309 labeling of endogenously expressed cathepsins in RAW-264.7 cells. Cells were treated with probe for 30
min in the presence or absence of cysteine cathepsin inhibitor E64d followed by lysis and analysis by SDS-PAGE and scanning for fluorescent
labeled proteins. The locations of cathepsin X, B/L, and S are indicated
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white-light images and these ROIs were subsequently
quantified on the fluorescent images with ImageJ.
Image-guided surgery
Two mice per time point were scanned with the IVIS
Spectrum. Time points were 1, 2, 4, 8, and 24 h after injec-
tion. After the mice were sacrificed via cervical dislocation
the tumor was surgically removed while using an image-
guided surgery system. At each time point, the surgical pro-
cedure was recorded for two mice, one mouse with the Ex-
plorer Air (SurgVision) and one mouse with the Spy Elite
(Novadaq). The working distance was 20 cm above the sur-
gical field. The upper part of the mice was covered to pre-
vent influence from the scattered fluorescence of the liver.
The Explorer Air has two LED lights for 800 nm illu-
mination and one LED light for white light illumination,
enabling both fluorescence and white light images to be
simultaneously recorded. The Spy Elite could only rec-
ord the fluorescent image. Therefore, when performing
image-guided surgery using the Spy Elite, the Explorer
air system was used to record the white light image.
After surgery, the tumor and the tissues of interest were
collected, formalin-fixed for 6 h in 4% PFA/PBS,
followed by overnight storage in 30% sucrose/PBS and
frozen with TissueTek O.C.T compound (Sakura).
Ex vivo tissue analysis
To enable further ex vivo analysis, tumor, muscle, and
spleen tissues of mice 24 h after probe injection were
sliced into 4-μm sections and, where needed, deparaffi-
nized for scanning with the Odyssey CLx flatbed
scanning system with the following settings: wavelength
= 800 nm, resolution = 21 μm, quality = high, intensity =
3. Next, these slides were stained with hematoxylin and
eosin (H&E). Macrophages were visualized with immu-
nohistochemical (IHC) staining for murine F4/80 with a
rat anti-mouse F4/80 antibody, clone: CI:A3 (Bio-Rad la-
boratories). After antigen retrieval for 15 min at 95 °C
with a citrate buffer (pH 6), slides were incubated with a
primary antibody with a dilution of 1:250 overnight.
Next, a rabbit anti-rat antibody (Dako) followed by a
peroxidase conjugated goat anti-rabbit antibody (Dako)
was used. Finally, 3-3′-diaminobenzidine was added to
visualize peroxidase activity. Slides were evaluated by a
pathologist.
Statistical analysis
All data are presented as mean ± standard error. An in-
dependent Student’s T test was performed to test differ-
ences between groups (GraphPad, Prism 7). A P value of
less than 0.05 was considered significant.
Results
qABP VGT-309 activation is inhibited in vitro by a
cathepsin activity inhibitor
The binding specificity of VGT-309 to cysteine cathep-
sins was evaluated in vitro by binding to RAW 264.7 cell
lysates. VGT-309 bound cathepsins B, L, X, and S in a
dose-dependent manner (Fig. 1c). Cathepsin binding to
VGT-309 was abolished when cells were pre-incubated
with the cysteine cathepsin inhibitor E64d.
VGT-309 demonstrates tumor-specific labeling in 4T1
tumor allografts
To preserve all sources of cathepsin proteases, including
macrophages, a 4T1 mammary tumor allograft mouse
model was chosen. Using an optimal fluorescence contrast
setting, the tumor margin could be delineated by the
fluorescent signal as soon as 1 h after injection of 20 nmol
VGT-309. In vivo tumor fluorescent signals continued to
increase up to 24 h after VGT-309 injection as demon-
strated by using a fixed gain setting (Fig. 2a). Ex vivo organ
biodistribution analysis confirmed that the fluorescent sig-
nal of tumors increased over time up to 24 h after VGT-
309 injection (Fig. 2b, Supplementary Fig. S2). In contrast,
the fluorescent signal of the background muscle tissues
remained stable at different time points post probe injec-
tion (Fig. 2b, Supplementary Fig. S2). This resulted in an
increased median tumor-to-background ratio, which was
as high as 15.1 in the group evaluated at 24 h after probe
injection (Fig. 2b). Based on these results, 24 h post probe
injection was selected as the time point for imaging in the
control group. In contrast to the experimental groups,
fluorescent signal was not detected in the lower mammary
fat pad of mice in the control group, as compared with the
experimental groups with tumor inoculated in that area
(Fig. 2a). Ex vivo organ biodistribution analysis revealed
comparable fluorescent signals in the same tissues be-
tween the experimental mice and the control mice, except
for the tumor (Fig. 3a, b). The strong signal in the liver
and kidneys was expected and consistent with the finding
that these tissues express high cathepsin levels [18].
VGT-309 fluorescent signal correlates with tumor-
infiltrated macrophages
To determine the possible cellular source of VGT-309
fluorescent signal, we performed IHC staining using the
murine macrophage marker F4/80. In the tumor tissue,
the VGT-309 fluorescent signal was localized to the F4/80
positive staining area. Some immune cell enriched areas
without F4/80 positive staining also demonstrated a high
fluorescent signal (Fig. 4b), whereas VGT-309 signal could
also be detected in the tumor area (Fig. 4d). In the spleen
tissue, the fluorescent signal delineated the red pulp of the
spleen, which also stained positive for F4/80
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(Supplementary Fig. S3A). For muscle tissue, no F4/80
positive staining was found (Supplementary Fig. S3B).
Image-guided surgery by intravenous injection of VGT-
309 in a 4T1 tumor allograft model
We further explored the potential utility of cathepsin-
targeted imaging using VGT-309 for guiding surgical re-
section of the 4T1 tumors. Fluorescent images from
each time point show clear tumor delineation after 2 h
using the Novadaq Spy Elite and delineation at every
time point with the Surgvision Explorer Air (Fig. 5a).
Image-guided surgery of mice 24 h after probe injec-
tion is shown in Video S1 and S2. The tumors were
well-delineated by the fluorescent signal before removal.
After tumor removal, the fluorescent signal in the tumor
bed decreased dramatically (Fig. 5b, Video S1 and S2).
Minor spillover signal was seen in the surgical cavity
stemming from expected high liver signal. Nevertheless,
in clinical practice, spillover signal is unlikely to be an
Fig. 2 In vivo and ex vivo tumor fluorescent signal increases over time after 20 nmol VGT-309 injection. a Representative fluorescent images from
the IVIS spectrum of tumor-bearing mice at different time points post intravenous injection VGT-309 and the control mouse without tumor
inoculation. Six mice were evaluated per group. The upper panels demonstrate fluorescent images with the same scale. The lower panels show
the optimal fluorescence contrast at each time point. b Quantitative fluorescent signal from the Pearl imager shows changes in fluorescent signal
of tumor and background muscle tissue and tumor-to-background ratio (TBR) at different time point after intravenous injection of VGT-309. n = 6
for each time point. All data are presented as mean ± standard error
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issue since the distance between breast and liver tissue
in humans is larger than in a mouse.
A biopsy was taken from the tumor bed after tumor
resection, which was confirmed to be muscle tissue by
histopathological examination (Fig. 5b).
Discussion
This study demonstrates that VGT-309 in combination
with optical fluorescent imaging can guide the surgical
resection of tumor in a breast tumor-bearing syngeneic
mouse model.
Unlike conventional imaging techniques, which dis-
criminate tumor from normal tissue based on morpho-
logical and/or architectural changes, tumor-targeted
optical molecular imaging enables in vivo real-time
tumor detection based on molecular alterations in tu-
mors [19]. This technique was first introduced in 2011
for intraoperatively guiding the surgical resection of tu-
mors in patients [20]. Several tumor-specific optical
fluorescent probes have been developed and investigated
in both preclinical and clinical studies for tumor detec-
tion and fluorescent image-guided surgery [21–29]. Re-
sults from early-phase clinical trials indicate that it is
feasible to incorporate fluorescent image-guided surgery
in standard of care surgical procedure, as fluorescent
image-guided surgery is safe for human use and had lim-
ited interference with the standard of care procedure
[23, 25, 27, 20]. Moreover, studies have demonstrated
potential clinical value of this technique in terms of im-
proving intraoperative detection of tumor deposits or
tumor positive resection margins [27, 28]. However,
many of these probes are antibody-based with an
optimal imaging time point several days after intraven-
ous injection due to their relatively slow distribution.
Therefore, patients need to have another visit to the hos-
pital before surgery. Rapidly distributing probes that enable
imaging several hours or one day after intravenous injection
are desirable for clinical practice. Our study demonstrated
that as soon as 1 h after VGT-309 injection, the tumor
could already be detected by the fluorescent signal with the
IVIS spectrum. Ex vivo, the tumor-to-background ratio in-
creased from 6.7 at 1 h to 15.1 at 24 h after probe injection.
Furthermore, the high tumor-to-background ratio clearly
differentiated tumor from normal tissue enabling image-
guided surgery already 2 h post VGT-309 administration
with both clinical imaging devices. VGT-309’s flexible im-
aging window of 2 to at least 24 h after injection makes it a
desirable probe for clinical practice.
To date, several biomarkers served as the targets in
the development of tumor-specific probes for tumor de-
tection in breast cancer. These markers include vascular
endothelial growth factor A (VEGFA) [30], human epi-
dermal growth factor receptor 2 (HER2) [31], gastrin-
releasing peptide receptor (GRPR), and integrin αvβ3
[32]. Probes targeting these biomarkers provided high
tumor-to-background ratio for tumor detection or guid-
ing surgical resection of tumors in preclinical and early-
phase clinical trials [21, 28, 32]. Limitations for these
biomarkers are, for example, that HER2 is overexpressed
in 20–30% [33], and GRPR in around 76% [34] of breast
cancer tumors. This limits the application of probes tar-
geting these markers in all breast cancer patients.
Moreover, probes targeting VEGFA, GRPR, and αvβ3
showed positive signal in normal tissue and false-
Fig. 3 Comparable pattern in VGT-309 organ biodistribution between the experimental mice (24 h post injection group) and the control mice. a
Representative fluorescent images of tissues from the experimental mice (upper panel) and the control mice (lower panel). b Quantitative
fluorescent signal of a. n = 6. Data are presented as mean ± standard error. An independent Student’s T test did not find significant differences
between groups
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negative tumor detection in early-phase clinical trials
[28, 32]. These results leave room for improvement for
breast tumor detection in the field of tumor-specific mo-
lecular imaging. Literature data showed that cathepsins,
in particular cathepsin B, L, C, and S, are overexpressed
in human primary breast cancer tissue and are associ-
ated with worse patient prognosis [11]. Both tumor-
associated macrophages and breast tumor cells express
cathepsins [35]. Our study showed that the qABP VGT-
309 specifically bound to cathepsins B, L, X, and S. In
in vivo experiments, this probe accumulated in breast
tumor tissue but not in surrounding normal tissue. As
expected, VGT-309 activation was also observed in the
liver, spleen, and kidney tissues in the present study.
This is probably due to cathepsin expression by resident
macrophages in the liver and spleen, or the clearance of
activated VGT-309 through the kidney, which may affect
the application of VGT-309 for tumor detection in these
organs. In line with literature, at the microscopic level
we also found VGT-309 accumulation in macrophage-
enriched areas and in areas with viable tumor cells. In
human breast cancer, the majority of tumor-associated
macrophages or tumor-infiltrating lymphocytes locate at
the invasive front (or “margin”) of the tumors [36, 37].
Together, these data support the further evaluation of
our probe VGT-309 on fluorescent image-guided intra-
operative surgical margin assessment in breast cancer.
Cathepsin-targeting probes have been investigated for
use in tumor detection and fluorescence-guided tumor
surgical resection in preclinical studies or early-phase
clinical trials [9, 10, 16, 38–44]. These probes are based
on fluorescently labeled inhibitors or substrates.
Substrate-based probes that do not include a tumor re-
tention strategy diffuse rapidly from their substrate,
resulting in fast clearance of the fluorescent signal from
the target location. Moreover, substrate-based probes do
not allow identification of the proteases which activate
the probes. This makes it difficult to assign signal
Fig. 4 Microscopic fluorescent signal of VGT-309 colocalizes with tumor-infiltrated immune cells including macrophages. a A representative
fluorescent image of a 4-μm-thick tumor slide from the mouse imaged 24 h after intravenous injection of VGT-309. Corresponding F4/80
immunohistochemical staining images of the areas highlighted by squares in a show b immune infiltrate containing few macrophages, c a high
presence of macrophages, and d tumor cells
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activated function to the probe-specific targets. For most
of the reported activity (inhibitor)-based probes, far-red
fluorophores are used for visualization of the probe-
targeting cathepsins [9, 10, 16, 40, 41, 43]. Although
promising tumor detection has been shown in preclinical
mouse models with far-red activity-based probes, the
low tissue penetration depth may prevent their use in
in vivo human cancer detection. Moreover, these far-red
fluorophores have not yet been approved for human use
by FDA or EMA. In this study, we overcome these hur-
dles by using a FDA and EMA approved near-infra red
fluorophore ICG for target visualization, which has a tis-
sue penetration depth up to 10mm and can be viewed
on widely available surgical imaging systems. This makes
the likelihood of clinical adoption of VGT-309 much
higher compared to non-ICG and far red fluorophores.
Conclusion
Due to the lack of an internationally standardized proto-
col for calibration of optical imaging devices, fluorescent
intensity of the same probe obtained from different im-
aging devices can be dramatically different. In this study,
we were able to use VGT-309 for guiding surgical resec-
tion of the implanted tumors with two different imaging
devices. This result supports future investigation on the
value of VGT-309 for fluorescent image-guided surgery
in patients with breast cancer. Since cathepsins are also
overexpressed in colorectal cancer, brain cancer, lung
cancer, ovarian cancer, and soft tissue sarcoma [11, 45],
VGT-309 can be considered for tumor delineation and
resection in many different types of cancers. Clinical
translation of VGT-309 is currently in progress.
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Additional file 1:. Figure S1. Structure of BMV109 and VGT-309. Figure
S2. Tumor fluorescent signal increases over time after VGT-309 injection.
Quantified fluorescent images of organs of interest from all the experi-
mental mice in different time points (1, 2, 4, 8 and 24 hours post VGT-309
injection). Figure S3. (A) Top left, a representative fluorescent image of a
4-μm thick slide of the spleen from the mouse imaged 24 hours after
intravenous injection of VGT-309. Top right, corresponding F4/80 immu-
nohistochemical staining images of the same tissue slide. Bottom, areas
highlighted by squares in top left. (B) Left, H&E staining of muscle tissue
imaged 24 hours after intravenous injection of VGT-309. Right, F4/80 im-
munohistochemical staining of the same muscle tissue.
Additional file 2: Video S1. Fluorescent image-guided surgery by the
Novadaq Spy Elite system 24 hours after intravenous injection of VGT-309.
Fig. 5 Image-guided surgery post intravenous injection of VGT-309. a Still images from Novadaq Spy Elite and SurgVision Explorer Air during
resection of 4T1 tumors on different time points after injection of VGT-309. b White light (left) and fluorescent (middle) images of the surgical
field before (upper) and after (lower) tumor removal using the Novadaq Spy Elite. H&E staining (right) histopathological analysis confirms that the
tissues highlighted in the white and red squares in the middle panels are breast tumor and muscle, respectively
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Additional file 3: Video S2. Fluorescent image-guided surgery by the
SurgVision Explorer Air system 24 hours after intravenous injection of
VGT-309.
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